MEDINOL LTD.
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 1992-12-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.medinol.com
First in Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease And/or Proximal Popliteal Artery Disease
- Conditions
- Popliteal Artery StenosisSuperficial Femoral Artery Stenosis
- Interventions
- Device: ChampioNIR Ridaforolimus Eluting Peripheral Stent System
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06410313
- Locations
- 🇺🇸
Piedmont Healthcare, Inc., Atlanta, Georgia, United States
🇺🇸Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH, New York, New York, United States
🇺🇸St Francis Hospital Heart Center, Roslyn, New York, United States
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
- Conditions
- Coronary Artery DiseaseCoronary Stenosis
- Interventions
- Device: IoNIR Ridaforolimus-Eluting Coronary Stent System
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06071702
IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
- Conditions
- Coronary StenosisCoronary DiseaseNon-ST Elevated Myocardial InfarctionCardiovascular Diseases
- Interventions
- Device: IoNIR Ridaforolimus-Eluting Coronary Stent System
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05364697
- Locations
- 🇧🇷
InCor, Sao Paulo, Brazil
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Rabin Medical Center, Petah tikva, Israel
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
- Conditions
- Coronary StenosisMyocardial IschemiaCardiovascular DiseasesCoronary Disease
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04761939
- Locations
- 🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Hillel Yafe Medical Center, Hadera, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
- Conditions
- Coronary Stenosis
- Interventions
- Device: Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 319
- Registration Number
- NCT03877848
- Locations
- 🇮🇱
Medinol LTD, Tel Aviv, Israel
ChampioNIR® SFA Stent EFS Study
- Conditions
- Peripheral Arterial Disease
- Interventions
- Device: ChampioNIR® SFA Stent
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03775226
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah tikva, Israel
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial
- Conditions
- Coronary Stenosis
- Interventions
- Combination Product: EluNIR Ridaforolimus Eluting Coronary Stent System
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03702608
- Locations
- 🇮🇱
Medinol LTD, Tel Aviv, Israel
BIONICS Israel Trial
- Conditions
- Stenosis
- Interventions
- Device: BioNIR Ridaforolimus Eluting Coronary Stent System
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT02834806
- Locations
- 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)
- Conditions
- de Novo or Restenosis Lesions
- Interventions
- Device: MedJ-01 Ridaforolimus Eluting Coronary Stent System
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT02828917
- Locations
- 🇯🇵
Shonan Kamakura General, Kamakura-City, Kanagawa, Japan
BIONICS - Pharmacokinetics (PK) Trial
- Conditions
- Heart Disease
- Interventions
- Device: BioNIR Ridaforolimus Eluting Coronary Stent
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02736344
- Locations
- 🇺🇸
Scottsdale Heart Group, Scottsdale, Arizona, United States
🇺🇸Cardiac and Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States